Friedreich Ataxia
An autosomal recessive disease, usually of childhood onset, characterized pathologically by degeneration of the spinocerebellar tracts, posterior columns, and to a lesser extent the corticospinal tracts. Clinical manifestations include GAIT ATAXIA, pes cavus, speech impairment, lateral curvature of spine, rhythmic head tremor, kyphoscoliosis, congestive heart failure (secondary to a cardiomyopathy), and lower extremity weakness. Most forms of this condition are associated with a mutation in a gene on chromosome 9, at band q13, which codes for the mitochondrial protein frataxin. (From Adams et al., Principles of Neurology, 6th ed, p1081; N Engl J Med 1996 Oct 17;335(16):1169-75) The severity of Friedreich ataxia associated with expansion of GAA repeats in the first intron of the frataxin gene correlates with the number of trinucleotide repeats. (From Durr et al, N Engl J Med 1996 Oct 17;335(16):1169-75)
Drugs by status
Approved for this indication (1)
Phase 4 trials (3)
Phase 3 trials (6)
Phase 2 trials (17)
Phase 1 trials (8)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (26)
- AbbVie
- Vidara Therapeutics
- Takeda
- Apotex
- Ipsen
- Bioelectron
- Penwest Pharmaceuticals Co.
- Reata Pharmaceuticals, Inc.
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Roma La Sapienza
- IRCCS Eugenio Medea
- McMaster University
- RWTH Aachen University
- University of Melbourne
- University of Rome Tor Vergata
- Mayo Clinic
- University of Naples Frederico II
- Free University of Brussels
- La Fundaction Para la Investigacion Biomedica, Madrid, Spain
- Cardero Therapeutics, Inc.
- Murdoch University
- Lundbeck
- Associazione Italiana per la lotta alle Sindromi Atassiche (AISA)
- Assistance Publique - Hôpitaux de Paris
- Minoryx Therapeutics, S.L.
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (1)